Radiology, Vol 192, 79-86, Copyright © 1994 by Radiological Society of North America

ARTICLES

F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer

R Bares, P Klever, S Hauptmann, D Hellwig, J Fass, U Cremerius, V Schumpelick, C Mittermayer and U Bull
Department of Nuclear Medicine, Technical University of Aachen, Germany.

PURPOSE: To evaluate positron emission tomography (PET) with fluorine- 18-labeled fluorodeoxyglucose (FDG) for detection of pancreatic cancer compared with computed tomography (CT) and ultrasonography (US). MATERIALS AND METHODS: Forty patients with suspected pancreatic cancer underwent static PET after intravenous injection of 150-300 MBq FDG. Focal FDG accumulation was regarded as a sign of malignancy and was quantitated by calculating differential uptake ratios (DURs) and tumor- liver ratios (TLRs). RESULTS: Malignancy was histologically proved in 27 patients. PET helped correctly classify 25 of 27 malignant conditions and 11 of 13 benign disorders. DUR and TLR were statistically significantly higher in malignant compared with benign disease (P < .01). False-negative findings were obtained in patients with insulin-dependent diabetes. False-positive findings were noted in a patient with retroperitoneal fibrosis and in one with pancreas divisum with chronic pancreatitis. PET was superior to CT and US in detection of lymph node metastases (13 of 17 vs three of 17 or one of 15, respectively. CONCLUSION: FDG PET has the potential to improve the detection of lymphadenopathy and the differential diagnosis of pancreatic masses.

This article has been cited by other articles:

				M. A. Blake, A. Singh, B. N. Setty, J. Slattery, M. Kalra, M. M. Maher, D. V. Sahani, A. J. Fischman, and P. R. Mueller Pearls and Pitfalls in Interpretation of Abdominal and Pelvic PET-CT RadioGraphics, September 1, 2006; 26(5): 1335 - 1353. [Abstract] [Full Text] [PDF]

				A.-J. Lemke, S. M. Niehues, N. Hosten, H. Amthauer, M. Boehmig, C. Stroszczynski, T. Rohlfing, S. Rosewicz, and R. Felix Retrospective Digital Image Fusion of Multidetector CT and 18F-FDG PET: Clinical Value in Pancreatic Lesions--A Prospective Study with 104 Patients J. Nucl. Med., August 1, 2004; 45(8): 1279 - 1286. [Abstract] [Full Text] [PDF]

				M. K. Kalra, M. M. Maher, G. W. Boland, S. Saini, and A. J. Fischman Correlation of Positron Emission Tomography and CT in Evaluating Pancreatic Tumors: Technical and Clinical Implications Am. J. Roentgenol., August 1, 2003; 181(2): 387 - 393. [Full Text] [PDF]

				B B Chin and R L Wahl 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies Gut, June 1, 2003; 52(90004): iv23 - 29. [Abstract] [Full Text] [PDF]

				T. Atsumi, J. Chesney, C. Metz, L. Leng, S. Donnelly, Z. Makita, R. Mitchell, and R. Bucala High Expression of Inducible 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase (iPFK-2; PFKFB3) in Human Cancers Cancer Res., October 15, 2002; 62(20): 5881 - 5887. [Abstract] [Full Text] [PDF]

				A. C. Buck, H. H. Schirrmeister, C.-A. Guhlmann, C. G. Diederichs, C. Shen, I. Buchmann, J. Kotzerke, D. Birk, T. Mattfeldt, and S. N. Reske Ki-67 Immunostaining in Pancreatic Cancer and Chronic Active Pancreatitis: Does In Vivo FDG Uptake Correlate with Proliferative Activity? J. Nucl. Med., May 1, 2001; 42(5): 721 - 725. [Abstract] [Full Text]

				S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps A Tabulated Summary of the FDG PET Literature J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93. [Full Text] [PDF]